Literature DB >> 18781882

Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.

David A Wohl1, David Waters, Ross J Simpson, Susan Richard, Amanda Schnell, Sonia Napravnik, Jessica Keys, J Joseph Eron, Priscilla Hsue.   

Abstract

In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18781882      PMCID： PMC5909814          DOI： 10.1086/592116

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.

Authors:  U H Iloeje; Y Yuan; G L'italien; J Mauskopf; S D Holmberg; A C Moorman; K C Wood; R D Moore
Journal:  HIV Med       Date:  2005-01       Impact factor: 3.180

3.  Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.

Authors:  Eugenia Negredo; José Moltó; Jordi Puig; Denise Cinquegrana; Anna Bonjoch; Núria Pérez-Alvarez; Raquel López-Blázquez; Asunción Blanco; Bonaventura Clotet; Celestino Rey-Joly
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

4.  Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.

Authors:  Blai Coll; Gerard Aragonés; Sandra Parra; Carlos Alonso-Villaverde; Lluis Masana
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

5.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.

Authors:  Virginia A Triant; Hang Lee; Colleen Hadigan; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2007-04-24       Impact factor: 5.958

6.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

7.  Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Authors:  John J P Kastelein; Fatima Akdim; Erik S G Stroes; Aeilko H Zwinderman; Michiel L Bots; Anton F H Stalenhoef; Frank L J Visseren; Eric J G Sijbrands; Mieke D Trip; Evan A Stein; Daniel Gaudet; Raphael Duivenvoorden; Enrico P Veltri; A David Marais; Eric de Groot
Journal:  N Engl J Med       Date:  2008-03-30       Impact factor: 91.245

8.  Combination antiretroviral therapy and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

9.  Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

Authors:  Frank van Leth; Prahpan Phanuphak; Erik Stroes; Brian Gazzard; Pedro Cahn; François Raffi; Robin Wood; Mark Bloch; Christine Katlama; John J P Kastelein; Mauro Schechter; Robert L Murphy; Andrzej Horban; David B Hall; Joep M A Lange; Peter Reiss
Journal:  PLoS Med       Date:  2004-10-19       Impact factor: 11.069

10.  Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.

Authors:  Matthew T Bennett; Kevin W Johns; Gregory P Bondy
Journal:  Lipids Health Dis       Date:  2007-06-13       Impact factor: 3.876
View more
  20 in total

Review 1.  Dyslipidemia and its Treatment in HIV Infection.

Authors:  Carl Grunfeld
Journal:  Top HIV Med       Date:  2010 Aug-Sep

Review 2.  Novel functions of PXR in cardiometabolic disease.

Authors:  Changcheng Zhou
Journal:  Biochim Biophys Acta       Date:  2016-02-26

3.  Management of dyslipidemia in HIV-infected patients.

Authors:  Carlos D Malvestutto; Judith A Aberg
Journal:  Clin Lipidol       Date:  2011-08

Review 4.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

5.  Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.

Authors:  S Oswald; H E Meyer zu Schwabedissen; A Nassif; C Modess; Z Desta; E T Ogburn; J Mostertz; M Keiser; J Jia; A Hubeny; A Ulrich; D Runge; M Marinova; D Lütjohann; H K Kroemer; W Siegmund
Journal:  Clin Pharmacol Ther       Date:  2012-02-01       Impact factor: 6.875

Review 6.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

Review 7.  Dyslipidemia and lipid management in HIV-infected patients.

Authors:  Janet Lo
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-04       Impact factor: 3.243

Review 8.  Ezetimibe: an update on its clinical usefulness in specific patient groups.

Authors:  Daniel Hammersley; Mark Signy
Journal:  Ther Adv Chronic Dis       Date:  2016-11-24       Impact factor: 5.091

9.  Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.

Authors:  Dominic Chow; Huichao Chen; Marshall J Glesby; Anthony Busti; Scott Souza; Janet Andersen; Sharon Kohrs; Julia Wu; Susan L Koletar
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

Review 10.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.